Efficacy and Safety of Circadin® in the Treatment of Primary Insomnia | Psychiatry
Links shared publicly online about this topic.
- 651total visits
Efficacy and Safety of Circadin® in the Treatment of Primary Insomnia | Psychiatry
View full resource at touchpsychiatry.com
Tags: Sleep Disorder, Insomnia, Pharma, Psychiatry, Psychology, Safety
Most Recently Shared on December 16, 2010 at 2:13 pm By:
Efficacy and Safety of Circadin® in the Treatment of Primary Insomnia http://bit.ly/fXKUtx
Safety and efficacy of antibiotics compared with appendicectomy for treatment of uncomplicated acute appendicitis: meta-analysis of randomised controlled trials | BMJ
bmj.com — “Safety and efficacy of antibiotics compared with appendicectomy for treatment of uncomplicated acute appendicitis: meta-analysis of randomised controlled trials | BMJ” View full resource at bmj.com
Most Recently Shared on April 5, 2012 at 10:30 pm By:
Antibiotics a safe and viable alternative to surgery for uncomplicated appendicitis, say experts http://t.co/p1sQDNb4
Brodalumab For Moderate To Severe Psoriasis Moving Into Phase III
medicalnewstoday.com — “Results from a Phase II, randomized, double-blind, placebo-controlled, dose-ranging trial designed to evaluate the efficacy and safety of brodalumab (formerly AMG 827) in 198 patients with moderat” View full resource at medicalnewstoday.com
Most Recently Shared on April 3, 2012 at 8:40 pm By:
Brodalumab For Moderate To Severe Psoriasis Moving Into Phase III: Results from a Phase II, randomized, double-b... http://t.co/fJik8Vz0
Urology News - Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial |3996338
mdlinx.com — “Urology Medical Article: Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial” View full resource at mdlinx.com
Most Recently Shared on March 29, 2012 at 4:11 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized... http://t.co/CiV3CZHC #urology
WHO | WHO Drug Information
who.int — “WHO | WHO Drug Information” View full resource at who.int
Most Recently Shared on March 28, 2012 at 2:34 pm By:
Damien Veauvy, PharmD Doctor, Pharmacist, and PharmD
WHO drug information journal. #regulatory #safety #efficacy http://t.co/SV8R2NZB
Pharmacy Implications with Enteral Nutrition
www2.gotomeeting.com — “Pharmacists must be knowledgeable about their patients' nutrition to provide complete care and maximize the efficacy and safety of concurrent medications. Many pharmacists are comfortable managing a patient's parenteral nutrition, but often are not involved in patient care relating to enteral nutrition, or "tube feeds." This includes the different components that constitute an enteral nutrition formulation, the interactions that may be present between enteral nutrit” View full resource at www2.gotomeeting.com
Most Recently Shared on March 27, 2012 at 8:38 pm By:
Our webinar on April 11 will review how pharmacists can help with enteral nutrition:... http://t.co/YrS32fqG
CSL Behring commences enrollment in SCIg PATH trial for CIDP
news-medical.net — “CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).” View full resource at news-medical.net
Most Recently Shared on March 26, 2012 at 5:12 pm By:
Meningitis News: CSL Behring commences enrollment in SCIg PATH trial for CIDP: CSL Behring has announced that th... http://t.co/zxaEok5p
Novel drug in pill form safer than standard approach to treat blocked lung blood vessels
medicalxpress.com — “A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism – a blockage of lung blood vessels usually caused by a clot – and showed comparable efficacy, according to data from the EINSTEIN-PE ...” View full resource at medicalxpress.com
Most Recently Shared on March 26, 2012 at 3:30 pm By:
PhysOrg Health News Health News
Novel drug in pill form safer than standard approach to treat blocked lung blood vessels http://t.co/tyxObO6R
Endocrinology News - Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study |3987965
mdlinx.com — “Endocrinology Medical Article: Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study” View full resource at mdlinx.com
Most Recently Shared on March 26, 2012 at 11:37 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide... http://t.co/E0ioKJGR #diabetes
Endocrinology News - Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study |3987965
mdlinx.com — “Endocrinology Medical Article: Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study” View full resource at mdlinx.com
Most Recently Shared on March 26, 2012 at 10:38 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in ... http://t.co/KXacAcru #endo
Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia
news-medical.net — “Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the Israeli Ministry of Health to initiate a Phase IIa clinical study evaluating the safety and efficacy of sustained erythropoietin therapy produced and delivered by the Company's EPODURE Biopumps.” View full resource at news-medical.net
Most Recently Shared on March 26, 2012 at 4:52 am By:
Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia: Medgenics, Inc., the developer of... http://t.co/H0y4VuEt
Statin Therapy: Assessing Intolerance, Drug Interactions, and Use in Renal Insufficiency | LinkedIn
events.linkedin.com — “PROGRAM OVERVIEW Statins dramatically reduce cardiovascular risk by lowering LDL-C levels, however, their use in some patients requires additional considerations, such as those with chronic kidney disease. In addition, there are significant safety and efficacy differences within the class that must be understood to ensure patients receive the optimal therapy and cardioprotective benefits of the class of drugs. Newer statins can achieve more pronounced LDL-C reductions at lower dosages, reducing ” View full resource at events.linkedin.com
Most Recently Shared on March 25, 2012 at 3:44 pm By:
James Underberg Doctor, Internist, and Physician
LinkedIn Events: Statin Therapy: Assessing Intolerance, Drug Interactions, and Use in Renal Insufficiency http://t.co/HLehljFL
Merck blood clot drug in limbo after mixed results - Yahoo! News
news.yahoo.com — “From Yahoo! News: CHICAGO (Reuters) - Impressive efficacy but worrisome bleeding was seen for a new type of blood clot preventer tested by Merck & Co in one of the largest heart-drug studies ever conducted, researchers said on Saturday, raising questions whether the company will seek approval of the drug and whether it can pass muster with regulators. Vorapaxar has been dogged by bleeding concerns since January 2011, when a safety committee overseeing the 26,449-patient study said the new type o” View full resource at news.yahoo.com
Most Recently Shared on March 24, 2012 at 3:52 pm By:
Merck blood clot drug in limbo after mixed results: CHICAGO (Reuters) - Impressive efficacy but worrisome bleedi... http://t.co/V3CP4aUx
Merck blood clot drug in limbo after mixed results - Yahoo! News
news.yahoo.com — “From Yahoo! News: CHICAGO (Reuters) - Impressive efficacy but worrisome bleeding was seen for a new type of blood clot preventer tested by Merck & Co in one of the largest heart-drug studies ever conducted, raising questions whether the company will seek approval of the drug and whether it can pass muster with regulators, researchers said on Saturday. Vorapaxar has been dogged by bleeding concerns since January 2011, when a safety committee overseeing the 26,449-patient study said the new type o” View full resource at news.yahoo.com
Most Recently Shared on March 24, 2012 at 2:34 pm By:
HealthTrendster Health Executive
Merck blood clot drug in limbo after mixed results - CHICAGO (Reuters) - Impressive efficacy but worrisome bleeding ... http://t.co/CSjRsD5J
Endocrinology News - The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |3961558
mdlinx.com — “Endocrinology Medical Article: The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials” View full resource at mdlinx.com
Most Recently Shared on March 23, 2012 at 11:57 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized cl... http://t.co/UZKoEbvU #endo
In Europe, Medical Devices Regulated No More Closely Than Toys from China | Qmed
qmed.com — “[Guardian (UK)] 1/9/2012 -- Many people would suppose that medical devices are subject to the same stringent approval and inspection processes as medicines. But they would be wrong. When it comes to devices such as hip joints and breast implants, a manufacturer is not required to win a licence based on evidence of safety and efficacy from clinical trials. Instead, they must get a CE mark which certifies the product reaches a certain European quality standard.” View full resource at qmed.com
Most Recently Shared on March 22, 2012 at 9:08 pm By:
Jeff Brandt Medical Technology, Health Executive, and Health IT
In Europe, Medical Devices Regulated No More Closely Than Toys from China | http://t.co/Z1E0yBNM ~good title
Advertisement
